Genmab - ADR

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Media Release COPENHAGEN , Denmark; March 28 , 20 23

Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer

Genmab A/S (GMAB) Q4 2022 Results Conference Call February 22, 2023 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Chief Operating Officer Tahamtan Ahmadi - Chief Medical Officer Conference Call Participants Matthew Harrison - Morgan Stanley Peter Verdult - Citigroup Sachin Jain - Bank of America Jonathan Chang - SVB Securities Elizabeth Walton - Crédit Suisse AG Paul Jeng - Guggenheim Securities Yaron Werber - Cowen and Company Emily Field - Barclays Asthika Goonewardene - Truist Securities, Inc Etzer Darout - BMO Capital Markets Matthew Phipps - William Blair & Company Operator Hello, and welcome to the Genmab Full-year 2022 Conference Call. As a reminder, this conference call is being recorded.

Genmab A/S (GMAB) Q4 2022 Earnings Call Transcript

Genmab Publishes 2022 Annual Report

Hologic

ServiceNow

Splunk

These top-ranked stocks are likely to beat on the bottom line in their next releases. These stocks include Genmab (GMAB), Hologic (HOLX), ServiceNow (NOW) and Splunk (SPLK).

4 Top Stocks to Buy on Earnings Beat Potential

Genmab (GMAB) is a Danish commercial biopharma company with a leading technology and track record in innovative antibody-based therapeutics. Darzalex royalty revenue is the key driver of the stock price and the bedrock of Genmab's strong performance during 2021-2022.

Genmab: High-Quality Biotech Darling, But Lacks Meaningful Catalysts In The Near Term

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022

Gilead Sciences

GILD vs. GMAB: Which Stock Is the Better Value Option?

GILD or GMAB: Which Is the Better Value Stock Right Now?

Correction to Company Announcement No. 1 of January 3, 2023

United Therapeutics

Vertex Pharmaceuticals

Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof.

3 Biotech Companies to Watch in 2023

Media Release COPENHAGEN, Denmark ; January 2 , 20 2 3 Genmab A/S (Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 41 st  Annual J.P. Morgan Healthcare Conference in San Francisco at 9:00 AM PST / 12 :00 PM EST / 6 : 00 PM CET on January 11, 2023. The live and archived webcast of the presentation will be available on Genmab's website at  https://ir.genmab.com/events-and-presentations#content .

Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference

AbbVie

Abbott Labs

Alnylam Pharmaceuticals

Amgen

argenx

AstraZeneca

Baxter

Bayer AG

BeiGene

Biogen

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Eli Lilly

Merck

Moderna

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Pfizer

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Royalty Pharma

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

Catalyst Pharmaceuticals

Inspire Medical Systems Inc

Medpace Holdings

These leading biotech stocks have had a good quarter and some may have room to run, while for others it's time to ring the register. The post Biotech And Medical Stocks Leading Performers As 2022 Draws To A Close appeared first on Investor's Business Daily.

Biotech And Medical Stocks Leading Performers As 2022 Draws To A Close

Ambac Financial Group

Comstock Resources

HF Sinclair Corp

Graphic Packaging Hld

Hess

Murphy Oil

NVIDIA

Occidental Petroleum

Pinduoduo Inc - ADR

Phillips 66

TotalEnergies SE

Valero Energy

Oil stocks dominate this list of today's fastest-growing stocks, all eyeing 100%-1,220% EPS gains this year. The post With Bear Market Scars, These 26 Stocks Expect Up To 1,220% Growth appeared first on Investor's Business Daily.

With Bear Market Scars, These 26 Stocks Expect Up To 1,220% Growth

COPENHAGEN, Denmark--( BUSINESS WIRE )--Genmab A/S (Nasdaq: GMAB):

Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Ligand Pharmaceuticals

LGND vs. GMAB: Which Stock Is the Better Value Option?

LGND or GMAB: Which Is the Better Value Stock Right Now?

Genmab to Hold 2022 R&D Update and ASH Data Review Meeting

Genmab A/S (Nasdaq: GMAB) today announced the results from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in combination with other therapies for the treatment of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), previously untreated FL, and Richter's Syndrome (RS). These data, along with additional results from the phase 1/2 EPCORE NHL-1 clinical trial, evaluating the safety and efficacy of epcoritamab in patients with R/R large B-cell lymphoma (LBCL), are being presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH), being held in New Orleans, Louisiana, and virtually, December 10-13, 2022.

Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Corcept Therapeutics

Bio-Techne

If there's a silver lining regarding the coronavirus pandemic, it's that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 crisis proved that when humanity comes together, it can foster incredible advancements at breakneck speed.

Our 7 Top Biotech Stock Picks for 2023

Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?

Celsius Holdings

Copa Hlds

Equinor

Horizon Pharma

Lattice Semiconductor

Monster Beverage

PepsiCo

An array of top stocks in a wide variety of industries are building cup bases as the stock market recovers. The post Top Stocks In Multiple Industries Build Bases As Market Gains Strength appeared first on Investor's Business Daily.

Top Stocks In Multiple Industries Build Bases As Market Gains Strength

Enphase Energy

Gartner

KnowBe4

UserTesting

Buy shares of Genmab (GMAB), KnowBe4 (KNBE), UserTesting (USER), Enphase Energy (ENPH) and Gartner (IT).

5 Top Stocks to Tap Earnings Beat Potential

Darzalex delivered strong growth in the third quarter, and Genmab increased the full-year guidance as a result. BLA submission for epcoritamab was accepted by the FDA and granted Priority Review.

Genmab: Darzalex Continues To Impress, Epcoritamab One Step Closer To Market

Harmony Biosciences Holdings

Neurocrine Biosciences

Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.

Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases

News for Genmab - ADR Stock (GMAB)